|Goran Ando (CEO)|
In 1999 the Company led consolidation in the UK biosciences market merging with Chiroscience plc and then buying Medeva plc. Then in 2000 it bought Cistron, a US biosciences business. It expanded into Germany in 2001 buying Thiemann, a German biosciences business, and went on to buy Oxford Glycosciences in July 2003 for £102m. Celltech was acquired by UCB, a Belgian drugmaker, in 2004. Since then it has been known as UCB Celltech.
The Company was engaged in research and development of therapies for patients with serious diseases. Products included:
- Tussionex for coughs
- Zaroxolyn for resistant edema
- Methylphenidate for ADHD
- Amphetamine for ADHD and narcolepsy, as 5 mg Dexedrine tablets
- Semprex-D, an antihistamine and decongestant
- Inotuzumab ozogamicin and gemtuzumab ozogamicin, both through Celltech's collaboration with Wyeth.
- UK Biotech Industry Consolidates As Celltech Buys Medeva for $915m[permanent dead link]
- UK's Celltech Buys Cistron of the US[permanent dead link]
- Celltech acquires German sales and marketing firm Thiemann for $44.6 mill
- ISIS Archived September 17, 2014, at the Wayback Machine.
- "Celltech sold to Belgian firm in £1.5bn deal". The Guardian. 18 May 2004.
- Businessweek: Celltech Group Archived September 8, 2012, at the Wayback Machine.
- Damle, NK; Frost, P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386–90. doi:10.1016/S1471-4892(03)00083-3. PMID 12901947.